Australia permits circulation of vaccines against cervical cancer

The Australian Drug Administration has just officially approved the use of cervical cancer vaccine, Cervarix ™, for women aged 10 to 45 years. This is the first country to use cervical cancer vaccine.

Vaccines to prevent cervical cancer and precancerous lesions are caused by the most common types of HPV viruses produced by a UK pharmaceutical company.

Australia is the first country to permit the use of vaccines against cervical cancer in women aged 10-45 years.(Casadepunk artwork)

According to Jean Stephenne, president of the company's Biopharmaceutical industry, the licensed vaccine for use in Australia is a new step in the process of eliminating the burden of cervical cancer for all women. More importantly, this is the first cervical cancer vaccine to be prescribed for women over 26 years of age.

The vaccine is formulated with a formula that includes a proprietary support system called AS04, which is used to increase the immune response and prolong the protection period of the vaccine.

Tested on more than 40,000 women in different clinical trials, the vaccine is highly effective against pre-cancerous lesions caused by human Pappiloma virus ( HPV) types 16 and 18. These are the two types that cause 70% of cervical cancer cases worldwide. In addition, the study shows early evidence of the protective effect of vaccines against infection with cervical cancer-causing HPV types other than type 16 and 18.

In March 2007, this cervical cancer vaccine was also registered with the Food and Drug Administration (FDA). Previously, the application was sent to the European Drug Administration, African, Asian and Latin American countries.

To date, more than 100 HPV types have been identified in humans, and about 15 of them have been identified as causing cervical cancer. Cervical cancer is the second most common cancer in women under 45 years of age and is the cause of death for 270,000 women a year globally.

H.Cat